search
Back to results

Optimal Postoperative Pain Management After Lung Surgery (OPtriAL)

Primary Purpose

Lung Cancer, Pain, Postoperative, VATS

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Thoracic epidural analgesia
Continuous regional paravertebral block
Single shot intercostal nerve block
Sponsored by
Maxima Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients (>18 years)
  • Patients referred for anatomic lung resection (pneumonectomy, (bi)lobectomy or segmentectomy for either benign or malignant disease) with the intention of performing it by video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS)
  • Patients should be able to provide informed consent and fill out questionnaires in Dutch language.

Exclusion Criteria:

  • Patients with contra-indications for TEA or PVB (infection at skin site, increased intracranial pressure, non-correctable coagulopathy, bridging indication for therapeutic anticoagulation (CHADS-VASc ≥ 8), sepsis and mechanical spine obstruction) or allergic reactions to local anaesthetics will be excluded.
  • Patients chronically using opioids for reasons not related to the operation will be excluded from the study since postoperative baseline opioid requirement will be higher and TEA remains the preferred technique for these patients.
  • In case the lung surgeon estimates the operation to be performed through a thoracotomy instead of VATS/RATS

Sites / Locations

  • Maxima MCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Thoracic epidural analgesia

Continuous regional paravertebral block

Single shot intercostal nerve block

Arm Description

See intervention description

See intervention description

See intervention description

Outcomes

Primary Outcome Measures

Pain scores
Proportion of pain scores ≥4 as assessed by the numerical rating scale (NRS) (measured from 0 until 10; lowest value signifying no pain and highest value signifying worst pain)
Quality of Recovery (QoR)
QoR measured with the QoR-15 questionnaire on postoperative 1 and 2 (maximum score of 150, the higher the score the better the outcome)

Secondary Outcome Measures

cumulative use of opioids and analgesics
total opioid and non-opioid consumption as supplementary analgesic requirement
postoperative complications
according to the Clavien-Dindo classification;
hospitalisation
defined as the total number of days in hospital after the surgical intervention (including readmissions within the first 30 postoperative days), the following standardised discharge criteria after surgery will be applied in all participating hospitals: normal intake of nutrition, independent mobility, absence of fever (<38 °C), and no presence of chest tube;
patient satisfaction
5-point Likert scale: not at all satisfied, slightly satisfied, neutral, very satisfied and extremely satisfied
degree of mobility
4-point scale: on the bed (1), to the chair (2), to the toilet (3), outside the patient's hospital room(4)

Full Information

First Posted
August 2, 2022
Last Updated
August 5, 2022
Sponsor
Maxima Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05491239
Brief Title
Optimal Postoperative Pain Management After Lung Surgery (OPtriAL)
Official Title
Optimal Postoperative Pain Management After Lung Surgery (OPtriAL): Multi-centre Randomised Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2021 (Actual)
Primary Completion Date
August 1, 2023 (Anticipated)
Study Completion Date
November 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maxima Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Adequate pain control after video-assisted thoracoscopic surgery (VATS) for lung resection is important to improve postoperative mobilisation, recovery, and to prevent pulmonary complications. So far, no consensus exists on optimal postoperative pain management after VATS anatomic lung resection. Thoracic epidural analgesia (TEA) is the reference standard for postoperative pain management following VATS. Although the analgesic effect of TEA is clear, it is associated with patient immobilisation, bladder dysfunction and hypotension which may result in delayed recovery and longer hospitalisation. These disadvantages of TEA initiated the development of unilateral regional techniques for pain management. The most frequently used techniques are continuous paravertebral block (PVB) and single-shot intercostal nerve block (ICNB). The investigators hypothesize that using either PVB or ICNB is non-inferior to TEA regarding postoperative pain and superior regarding quality of recovery (QoR). Signifying faster postoperative mobilisation, reduced morbidity and shorter hospitalisation, these techniques may therefore reduce health care costs and improve patient satisfaction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Pain, Postoperative, VATS, Locoregional Anaesthesia, Thoracic Epidural

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a multi-centre randomised three-arm trial comparing continuous PVB, single-shot ICNB and TEA in a 1:1:1 ratio in patients who will undergo a VATS anatomic lung resection. We use a non-inferiority design with respect to the outcome measure 'pain' and a concomitant superiority design regarding 'quality of recovery'.
Masking
None (Open Label)
Masking Description
As the analgesic strategies highly differ in nature (with or without percutaneous catheter) and/or postoperative care (mobility with or without prerequisites, urinary catheter placement), blinding for the randomised strategy is unfeasible.
Allocation
Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Thoracic epidural analgesia
Arm Type
Active Comparator
Arm Description
See intervention description
Arm Title
Continuous regional paravertebral block
Arm Type
Experimental
Arm Description
See intervention description
Arm Title
Single shot intercostal nerve block
Arm Type
Experimental
Arm Description
See intervention description
Intervention Type
Procedure
Intervention Name(s)
Thoracic epidural analgesia
Intervention Description
After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
Intervention Type
Procedure
Intervention Name(s)
Continuous regional paravertebral block
Intervention Description
The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter. Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour.
Intervention Type
Procedure
Intervention Name(s)
Single shot intercostal nerve block
Intervention Description
At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
Primary Outcome Measure Information:
Title
Pain scores
Description
Proportion of pain scores ≥4 as assessed by the numerical rating scale (NRS) (measured from 0 until 10; lowest value signifying no pain and highest value signifying worst pain)
Time Frame
Postoperative day 0-2
Title
Quality of Recovery (QoR)
Description
QoR measured with the QoR-15 questionnaire on postoperative 1 and 2 (maximum score of 150, the higher the score the better the outcome)
Time Frame
Postoperative day 1-2
Secondary Outcome Measure Information:
Title
cumulative use of opioids and analgesics
Description
total opioid and non-opioid consumption as supplementary analgesic requirement
Time Frame
Postoperative day 0 until 3 as well as the use and dosage of opioid use at the follow-up period 2-3 weeks after the operation
Title
postoperative complications
Description
according to the Clavien-Dindo classification;
Time Frame
until 2-3 weeks of follow-up
Title
hospitalisation
Description
defined as the total number of days in hospital after the surgical intervention (including readmissions within the first 30 postoperative days), the following standardised discharge criteria after surgery will be applied in all participating hospitals: normal intake of nutrition, independent mobility, absence of fever (<38 °C), and no presence of chest tube;
Time Frame
30 postoperative days
Title
patient satisfaction
Description
5-point Likert scale: not at all satisfied, slightly satisfied, neutral, very satisfied and extremely satisfied
Time Frame
Postoperative day 0 until 3
Title
degree of mobility
Description
4-point scale: on the bed (1), to the chair (2), to the toilet (3), outside the patient's hospital room(4)
Time Frame
Postoperative day 0 until 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (>18 years) Patients referred for anatomic lung resection (pneumonectomy, (bi)lobectomy or segmentectomy for either benign or malignant disease) with the intention of performing it by video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS) Patients should be able to provide informed consent and fill out questionnaires in Dutch language. Exclusion Criteria: Patients with contra-indications for TEA or PVB (infection at skin site, increased intracranial pressure, non-correctable coagulopathy, bridging indication for therapeutic anticoagulation (CHADS-VASc ≥ 8), sepsis and mechanical spine obstruction) or allergic reactions to local anaesthetics will be excluded. Patients chronically using opioids for reasons not related to the operation will be excluded from the study since postoperative baseline opioid requirement will be higher and TEA remains the preferred technique for these patients. In case the lung surgeon estimates the operation to be performed through a thoracotomy instead of VATS/RATS
Facility Information:
Facility Name
Maxima MC
City
Veldhoven
ZIP/Postal Code
5504 DB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louisa Spaans, MD
Phone
+31-408887243
Email
louisa.spaans@mmc.nl
First Name & Middle Initial & Last Name & Degree
Frank van den Broek, MD, PhD
Phone
+31-408888550
Email
frankvanden.broek@mmc.nl

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will become available for non-commercial scientific research (open access) after a period of 12 months after the last data collection. Data request can be done by contacting the PI.
Citations:
PubMed Identifier
36058900
Citation
Spaans LN, Dijkgraaf MGW, Meijer P, Mourisse J, Bouwman RA, Verhagen AFTM, van den Broek FJC; OPtriAL study group. Optimal postoperative pain management after VATS lung resection by thoracic epidural analgesia, continuous paravertebral block or single-shot intercostal nerve block (OPtriAL): study protocol of a three-arm multicentre randomised controlled trial. BMC Surg. 2022 Sep 4;22(1):330. doi: 10.1186/s12893-022-01765-y.
Results Reference
derived

Learn more about this trial

Optimal Postoperative Pain Management After Lung Surgery (OPtriAL)

We'll reach out to this number within 24 hrs